BWX Technologies submits Drug Master File to FDA for Actinium-225 API

BWXT Medical Ltd. has submitted a Drug Master File to the U.S. Drug and Food Administration FDA for No Carrier Added Actinium-225 Active Pharmaceutical Ingredient. Ac-225 is an alpha-emitting isotope used in targeted alpha therapies that combine the isotope with specific tumor-seeking targeting vectors to kill cancer cells while minimizing the impact to healthy tissues.